Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for GVHD Prophylaxis Following Omidubicel HCT
NCT06731504Phase 1Recruiting
- Sponsor
- Duke University
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in graft-versus-host disease (GVHD), sponsored by Duke University. Primary endpoints: Frequency of adverse events at 6 months, Severity of adverse events at 6 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06731504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731504.